Viatris Shares Encouraging Results for XULANE LO Low Dose Patch in Birth Control Study Viatris's Phase 3 study of the XULANE LO low dose contraceptive patch shows promising efficacy and safety, paving the way for a FDA submission in 2025.

Viatris Shares Encouraging Results for XULANE LO Low Dose Patch in Birth Control Study #United_States #Pittsburgh #Viatris #XULANE #Birth_Control